Institute for Glycomics, Griffith University Gold Coast Campus, Queensland 4222, Australia.
Institute for Glycomics, Griffith University Gold Coast Campus, Queensland 4222, Australia.
J Mol Biol. 2014 Apr 3;426(7):1439-51. doi: 10.1016/j.jmb.2013.12.004. Epub 2013 Dec 8.
Galectins have essential roles in pathological states including cancer, inflammation, angiogenesis and microbial infections. Endogenous receptors include members of the lacto- and neolacto-series glycosphingolipids present on mammalian cells and contain the tetrasaccharides lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) that form their core structural components and also ganglio-series glycosphingolipids. We present crystallographic structures of the carbohydrate recognition domain of human galectin-3, both wild type and a mutant (K176L) that influenced ligand affinity, in complex with LNT, LNnT and acetamido ganglioside a-GM3 (α2,3-sialyllactose). Key structural features revealed include galectin-3's demonstration of a binding mode towards gangliosides distinct from that to the lacto/neolacto-glycosphingolipids, with its capacity for recognising the core β-galactoside region being challenged when the core oligosaccharide epitope of ganglio-series glycosphingolipids (GM3) is embedded within particular higher-molecular-weight glycans. The lacto- and neolacto- glycosphingolipids revealed different orientations of their terminal galactose in the galectin-3-bound LNT and LNnT structures that has significant ramifications for the capacity of galectin-3 to interact with higher-order lacto/neolacto-series glycosphingolipids such as ABH blood group antigens and the HNK-1 antigen that is common on leukocytes. LNnT also presents an important model for poly-N-acetyllactosamine-containing glycans and provides insight into galectin-3's accommodation of extended oligosaccharides such as the poly-N-acetyllactosamine-modified N- and O-glycans that, via galectin-3 interaction, facilitate progression of lung and bladder cancers, respectively. These findings provide the first atomic detail of galectin-3's interactions with the core structures of mammalian glycosphingolipids, providing information important in understanding the capacity of galectin-3 to engage with receptors identified as facilitators of major disease.
半乳糖凝集素在包括癌症、炎症、血管生成和微生物感染在内的病理状态中具有重要作用。内源性受体包括存在于哺乳动物细胞上的乳酰和新乳酰系列糖脂中的成员,并且包含四糖乳糖-N-四糖(LNT)和乳糖-N-新四糖(LNnT),它们构成其核心结构成分,还包括神经节系列糖脂。我们展示了人半乳糖凝集素-3 的碳水化合物识别结构域的晶体结构,包括野生型和一个影响配体亲和力的突变体(K176L),与 LNT、LNnT 和乙酰氨基神经节苷脂 a-GM3(α2,3-唾液乳糖)复合物。揭示的关键结构特征包括半乳糖凝集素-3 对神经节苷脂的结合模式与对乳酰/新乳酰糖脂的结合模式不同,当神经节苷脂糖脂(GM3)的核心寡糖表位嵌入特定的高分子量聚糖中时,其识别核心 β-半乳糖苷区域的能力受到挑战。乳糖和新乳酰糖脂在半乳糖凝集素-3 结合的 LNT 和 LNnT 结构中显示出其末端半乳糖的不同取向,这对半乳糖凝集素-3 与更高阶的乳酰/新乳酰糖脂相互作用的能力具有重要影响,例如 ABH 血型抗原和常见于白细胞上的 HNK-1 抗原。LNnT 也为含有多-N-乙酰乳糖胺的聚糖提供了一个重要模型,并深入了解了半乳糖凝集素-3 对扩展寡糖的容纳能力,例如多-N-乙酰乳糖胺修饰的 N-和 O-聚糖,通过半乳糖凝集素-3 相互作用,分别促进肺癌和膀胱癌的进展。这些发现提供了半乳糖凝集素-3 与哺乳动物糖脂核心结构相互作用的第一个原子细节,为理解半乳糖凝集素-3 与被确定为主要疾病促进剂的受体结合的能力提供了重要信息。